Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-cash Items (2020 - 2024)

Historic Non-cash Items for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q4 2024 value amounting to $37.3 million.

  • Apellis Pharmaceuticals' Non-cash Items fell 8531.11% to $37.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $37.3 million, marking a year-over-year decrease of 8531.11%. This contributed to the annual value of $37.3 million for FY2024, which is 45572.11% up from last year.
  • As of Q4 2024, Apellis Pharmaceuticals' Non-cash Items stood at $37.3 million, which was down 8531.11% from $253.9 million recorded in Q4 2023.
  • In the past 5 years, Apellis Pharmaceuticals' Non-cash Items registered a high of $317.0 million during Q4 2022, and its lowest value of $6.1 million during Q4 2020.
  • Over the past 5 years, Apellis Pharmaceuticals' median Non-cash Items value was $253.9 million (recorded in 2023), while the average stood at $181.2 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Non-cash Items soared by 471400.53% in 2021 and then plummeted by 8531.11% in 2024.
  • Apellis Pharmaceuticals' Non-cash Items (Quarter) stood at $6.1 million in 2020, then soared by 4714.01% to $291.8 million in 2021, then increased by 8.64% to $317.0 million in 2022, then fell by 19.9% to $253.9 million in 2023, then tumbled by 85.31% to $37.3 million in 2024.
  • Its last three reported values are $37.3 million in Q4 2024, $253.9 million for Q4 2023, and $317.0 million during Q4 2022.